The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial

Trial Profile

The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Gout
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors Menarini
  • Most Recent Events

    • 28 Jul 2017 This study has been completed in Netherlands (End Date: 11-09-2015).
    • 10 Jun 2017 Biomarkers information updated
    • 21 Dec 2016 Planned number of patients changed from 182 to 197.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top